In summary, the findings of this study demonstrate that, owing to their high activity and sensitivity to the microenvironment, intestinal CD11b+ B cells are the major source of IgA production, with therapeutic potential for intestinal diseases, such as colitis. This evidence concerns the gene ITGAM and colitis.